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emptive therapies. We hypothesize that T-cell receptor (TCR)
diversity after double umbilical cord blood transplantation
(dUCBT) will predict clinical outcomes.
Methods: 42 adult dUCBT recipients received ﬂudarabine,
melphalan, ATG with tacrolimus/sirolimus as GvHD pro-
phylaxis. TCRb CDR3 regions were ampliﬁed from unsorted
PBMCs and sequenced using the ImmunoSeq platform
(Adaptive Biotechnologies) at 3, 6 and 12 months after
dUCBT. Samples analyzed had predominantly donor T-cell
chimerism and no morphologic relapse. We analyzed 34
samples at 3 mos, 26 at 6 mos and 23 at 12 mos. Entropy/
Shannon’s diversity index and richness/Fisher’s alpha di-
versity were calculated from number and frequency of TCRb
sequences and normalized for sequencing depth. Higher
entropy and richness, measures of uncertainty and unseen
species within a complex population, reﬂect increased
diversity.
Results: Median age was 52 years (19-67). 57.1% were in
remission at dUCBT. Primary indications for dUCBT were
AML, NHL and MDS. Median follow-up among survivors was
47 months (18-91). 4-year OS was 41%; 4-year PFS was 26%.
As a whole, dUCBT recipients increased entropy and richness
of their T cell repertoire in the ﬁrst year. We categorized
subjects into 3 groups: relapse, NRM, or alive with neither
event. In the NRM cohort, median entropy and richness
values rose slightly from 3 to 6 mos then fell at 12 mos. In
comparison, median entropy and richness were higher in the
no event cohort between 3 and 12mos and rose substantially
to diversity levels found in healthy donors. (p¼0.01, 0.09,
0.004 for entropy at 3,6,12 mos; p¼0.06, 0.11, 0.006 for
richness at 3,6,12 mos). (Figure) Entropies of subjects who
relapsed did not differ from those of the no event cohort (not
depicted). In a similar analysis, entropy values for subjects
with chronic GvHD fell between 3 and 12 mos and were
signiﬁcantly lower than in subjects without any cGvHD,
relapse, or NRM at 12 mos (median entropy 5.9 vs 12.3,
p¼0.04). Inmultivariable analyses controlling for age, patient
sex, disease status, and diagnosis, high entropy was associ-
ated with lower NRM (HR 0.68, p<0.001), PFS (HR 0.79,
p¼0.009) and OS (HR 0.73, p¼0.005). High richness (log10
transformed) was associated with lower NRM (HR 0.3,
p<0.001) and OS (HR 0.30, p¼0.0003).
Conclusion: T-cell repertoire diversity as early as 3 months
after dUCBT is signiﬁcantly lower in subjects who eventuallyexperience NRM or cGvHD and does not expand with time
after transplant. These quantitative predictive indicesmay be
used to identify dUCBT recipients who merit more intensive
monitoring or prophylactic strategies against infection and
GvHD.377
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Background: Monitoring of cytomegalovirus (CMV) DNA by
PCR followed by preemptive treatment of CMV viremia
(CMVV) is an acceptable preventive strategy to reduce the
incidence of CMV tissue invasive disease (TID) after alloge-
neic hematopoietic cell transplant (HCT). Despite proactive
monitoring, some patients develop CMV TID leading to
adverse outcomes. We seek to characterize risk factors
associated with the development of CMV TID in HCT re-
cipients who were monitored and treated preemptively.
Methods: We reviewed the charts of 256 adult HCT re-
cipients, actively monitored for CMVV between January 1,
2009 and July 31, 2013. Our center preemptively monitors
allogeneic HCT recipients with weekly CMVDNA by PCR until
Day + 100, and thereafter every 2 weeks in patients with
GVHD. Antiviral therapy was initiated within 1 day of iden-
tifying signiﬁcant CMVV. Patients with CMV TID occurring
during preemptive monitoring were matched 1:1 by the
underlying disease, year of transplant, and time of follow-up
with controls that developed CMVV without TID.
Results: Of the 15 patients that developed CMV TID despite
preemptive therapy, 10 (66.7%) occurred within the ﬁrst 100
days following HCT. Median time from HCT to CMV TID was
62 days (range 25 -1137). All cases were gastrointestinal CMV
TID with 1 case of CMV-associated oral mucositis. 9/15 (60%)
had concurrent CMVV at the time of CMV TID diagnosis, and
4/15 (26%) were preemptively being treated with antivirals
for CMVV at the time of CMV TID diagnosis. The mean viral
load was 1,738.5 copies DNA/mL, range (0-9,699 copies DNA/
mL). 6/15 (40%) had at least one prior episode of CMVVwhich
had previously resolved. When compared with controls
there were no signiﬁcant differences in age, type of HCT, time
to CMV TID, conditioning therapy, donor matching, comor-
bidities, GVHD, level of initial CMVV, or CMV donor/recipient
serological status. No ganciclovir resistance was identiﬁed in
patients with CMV TID.
Conclusions: All cases of CMV TID were gastrointestinal
disease and tended to occur early after HCT. CMV TID
developed in the majority without preceding viremia. There
were no risk factors that could speciﬁcally identify patients
likely to develop CMV TID despite pre-emptive monitoring
and treatment. Gastrointestinal CMV TID remains an
inherent complication of a CMV preemptive strategy.378
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